Nektaria Kritsotaki

Nektaria Kritsotaki


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDimitrios Diamantidis
Dimitrios Diamantidis
KNKonstantinos Nikolettos
Konstantinos Nikolettos
NKNektaria Kritsotaki
Nektaria Kritsotaki
ATAngeliki Tiptiri-Kourpeti
Angeliki Tiptiri-Kourpeti
NNNikos Nikolettos
Nikos Nikolettos
CKChristos Kalaitzis
Christos Kalaitzis
Background: Advanced paternal age is increasingly encountered in assisted reproduction as parenthood is deferred. The clinical question is whether paternal age from about 40 to 45 years and older affects embryo development or outcomes, and to what extent any effect relates to the sperm epigenome. Methods: This narrative review synthesized PubMed-indexed evidence on sperm aging biology, including DNA methylation, chromatin packaging and nucleosome retention, small non-coding RNAs, telomere dynamics, DNA fragmentation, and oxidative and mitochondrial stress, and their potential clinical impact on assisted reproduction outcomes. Results: Maternal age remains the principal determinant of embryo aneuploidy. After multivariable adjustment, independent paternal-age effects on fertilization, blastocyst formation, and preimplantation genetic testing for aneuploidy are small or not detected. At very advanced paternal ages near or above 50 years, some studies report higher miscarriage and lower live birth, without a consistent change in early embryo morphology. Aging in men is linked to higher DNA fragmentation and oxidative and mitochondrial signatures, together with reproducible sperm-epigenome changes, including age-linked DNA methylation, altered histone retention, and small-RNA shifts. These molecular findings support modest intergenerational influences on early development, while stable transgenerational inheritance in humans is not supported. Conclusions: Advanced paternal age should be regarded as a risk modifier rather than a primary driver of preimplantation failure. Counseling should emphasize realistic effect sizes and the predominance of maternal age. Laboratory workflows should minimize oxidative stress. Selective DNA-fragmentation testing may be appropriate in recurrent ART failure or recurrent loss. Sperm-epigenome assays remain investigational and should undergo prospective, standardized validation before use in routine care.

30 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NKNektaria Kritsotaki
Nektaria Kritsotaki
DDDimitrios Diamantidis
Dimitrios Diamantidis
NKNikoleta Koutlaki
Nikoleta Koutlaki
NMNIKOLAOS MACHAIRIOTIS
NIKOLAOS MACHAIRIOTIS
PTPanagiotis Tsikouras
Panagiotis Tsikouras
Background/Objectives: Artificial intelligence (AI) models are increasingly applied across the assisted reproductive technology (ART) workflow, including male-factor assessment, ovarian stimulation, endometrial receptivity evaluation, embryo selection and prediction of pregnancy outcomes. However, many systems remain difficult to interpret, raising concerns regarding transparency, clinical integration and patient communication. Explainable artificial intelligence (XAI) aims to address these limitations by making model behavior more accessible to clinicians and embryologists. This review aimed to provide a narrative, concept-driven synthesis of how XAI has been implemented in ART, to critically examine methodological quality and clinical relevance and to outline priorities for responsible translation into practice. Methods: A structured narrative review was conducted using PubMed/MEDLINE as the primary database, supplemented by targeted reference-list screening of key primary studies and recent cross-disciplinary reviews relevant to AI in ART. Studies were curated and classified according to stage of the ART workflow, data modality, model family, explanation technique and validation strategy. Methodological features, performance reporting and implementation considerations were qualitatively appraised. Results: Most XAI applications in ART fall into two dominant categories: (i) feature-attribution methods such as SHAP and LIME applied to tabular clinical and laboratory data and (ii) saliency-based approaches, including Grad-CAM and related techniques, applied to embryo and ultrasound imaging. These methods can improve transparency and support counselling by clarifying which variables or image regions influence predictions. However, the majority of studies are retrospective and single centre, with limited external validation and heterogeneous outcome definitions, often prioritising clinical pregnancy over live birth. Calibration, decision-analytic evaluation and prospective assessment remain uncommon. XAI outputs are frequently interpreted as biologically causal despite being derived from observational data, highlighting the need for cautious clinical framing. Conclusions: XAI in ART has progressed from proof-of-concept demonstrations to early clinically oriented tools, but robust validation, standardised reporting and thoughtful workflow integration are still needed. Explanations can enhance auditability and communication, yet they do not compensate for methodological weakness. Future progress will depend on higher-quality multi-centre data, evaluation beyond discrimination metrics and governance frameworks that ensure transparency, fairness and sustained performance in real-world practice.

20 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NKNektaria Kritsotaki
Nektaria Kritsotaki
DDDimitrios Diamantidis
Dimitrios Diamantidis
NKNikoleta Koutlaki
Nikoleta Koutlaki
NMNIKOLAOS MACHAIRIOTIS
NIKOLAOS MACHAIRIOTIS
PANAGIOTIS TSIKOURASPANAGIOTIS TSIKOURAS
PANAGIOTIS TSIKOURAS
Background/Objectives: Recurrent pregnancy loss (RPL) has traditionally been investigated predominantly through maternal factors, while the clinical role of paternal assessment remains inconsistently defined. Current guidelines differ substantially regarding semen analysis, sperm DNA fragmentation (SDF), genetic testing, and referral for andrological evaluation. This review aimed to compare contemporary guideline recommendations, critically appraise the directness, prognostic value, and clinical utility of the supporting evidence, and classify paternal assessment strategies as routine, selective, or investigational. Methods: A structured narrative review was conducted using PubMed and Scopus searches through June 2026. International RPL, obstetric, reproductive medicine, and andrology guidelines were compared. Evidence from systematic reviews, meta-analyses, clinical studies, and clinically relevant molecular investigations was evaluated according to its directness to RPL populations, diagnostic and prognostic value, and evidence that test-guided interventions improve miscarriage or live-birth outcomes. Results: Routine paternal assessment should include age, reproductive and medical history, body weight, lifestyle, medication exposure, and relevant environmental or occupational risks. Conventional semen analysis is appropriate primarily when RPL coexists with infertility or suspected male reproductive disease. SDF is the most extensively studied advanced paternal biomarker and is frequently elevated in RPL cohorts, but findings vary by assay and comparator population, while prospective prediction of subsequent live birth and benefit from SDF-directed treatment remain unproven. Parental karyotyping has established counselling value but should be risk-stratified. Sperm aneuploidy testing, oxidative stress assays, seminal microbiome profiling, epigenetic biomarkers, and biomarker-directed interventions remain investigational. Conclusions: Paternal assessment in RPL should be couple-based, clinically targeted, and evidence-informed. Current evidence supports routine clinical evaluation, selective use of semen analysis, SDF testing, genetic assessment, and reproductive urology referral, and restriction of unvalidated biomarkers and treatments to research settings.